Last Updated: 02/12/2024
CHMI-transmission models for evaluating P. vivax and P. falciparum transmission-blocking interventions
Objectives
This project proposes to establish the first Controlled Human Malaria Infection (CHMI)-transmission models for P. falciparum in Burkina Faso and both P. falciparum and P. vivax in Ethiopia.
Malaria remains a major global health problem across Africa. In order to control and eliminate malaria it is essential to interrupt the highly efficient process of transmission; transmission-blocking vaccines (TBVs) could play a key role here. Although several TBV candidates have been identified, the path for clinical evaluation is not well defined, increasing the risk that vaccine candidates are progressed to large, complex, expensive and lengthy cluster-randomised trials. Controlled Human Malaria Infection (CHMI) models gained a prominent ‘bridging’ role in the early evaluation of candidate pre-erythrocytic- and blood-stages P. falciparum vaccines in malaria-naïve volunteers. Recently, P. falciparum and P. vivax CHMI-transmission models were successfully pioneered in malaria naïve volunteers. Both sites with different malaria endemicity have excellent clinical and mosquito infrastructure. This project will build a collaborative network with on site capacity to conduct and evaluate CHMI-transmission studies using with local parasite strains and mosquitoes. These CHMI-trans models will be strong assets to test TBV’s that may reduce and eventually eliminate malaria transmission.
May 2019 — Nov 2019
$21,989
Related Resources
